Optimizing cell lines for a Hepatitis B vaccine
Task V24: Cell line optimization and pre-master bank generation for a Hepatitis B Virus (HBV) vaccine
This study is working on creating a new vaccine to protect against Hepatitis B, which could help patients by providing a reliable way to prevent this virus in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International AIDS Vaccine Initiative NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10787972 on NIH RePORTER |
What this research studies
This research focuses on developing and optimizing cell lines to produce a vaccine for Hepatitis B Virus (HBV). It involves planning and assessing the feasibility of vaccine production, ensuring compliance with regulatory standards, and preparing for clinical trials. The goal is to create a reliable and effective vaccine that can be manufactured under stringent guidelines, ultimately contributing to the fight against infectious diseases. Patients may benefit from the eventual availability of a new vaccine that protects against HBV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of Hepatitis B infection, including those with chronic liver disease or those in high-risk populations.
Not a fit: Patients who are already vaccinated against Hepatitis B or those with no risk factors for the virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new and effective vaccine for Hepatitis B, significantly reducing the incidence of this infectious disease.
How similar studies have performed: Previous research has shown success in developing vaccines using optimized cell lines, indicating a promising approach for this project.
Where this research is happening
New York, United States
- International AIDS Vaccine Initiative — New York, United States (Active)
Researchers
- Principal investigator: Hassel, Thomas — International AIDS Vaccine Initiative
- Study coordinator: Hassel, Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.